Evaluating Spectral CT for Cardiotoxicity in Lymphoma Patients Treated with Anthracyclines

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of Spectral CT imaging in detecting acute and chronic cardiac toxicity in patients with Hodgkin's lymphoma and diffuse large B-cell lymphoma who are receiving anthracycline-based treatments. By utilizing advanced imaging techniques, the study aims to identify early signs of myocardial damage, such as edema and fibrosis, which are critical for timely cardioprotective interventions. The research focuses on enhancing routine oncological follow-ups with Spectral CT to improve patient outcomes related to cardiac health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with Hodgkin's lymphoma or diffuse large B-cell lymphoma (DLBCL) undergoing treatment regimens including anthracyclines
* Age ≥18 years
* Informed consent obtained

Exclusion Criteria:

* Absolute or relative contraindications to CT examination and/or administration of iodinated contrast agents (e.g., pregnancy, severe renal insufficiency in non-dialysis patients with GFR \<15-30 ml/min/1.73m²).
* Patients with a concomitant positive history of cardiovascular disease (e.g., myocardial infarction, known coronary artery disease, heart failure, arrhythmias, prior myocarditis, cardiomyopathies).
* History of mediastinal radiotherapy.

Where it's running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna
  Bologna, Italy Recruiting

Study contacts

• Principal investigator: Vincenzo Russo, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Vincenzo Russo, MD
• Email: vincenzo.russo@aosp.bo.it
• Phone: +390512144747

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Spectral CT to Diagnose Myocarditis in Patients with Chest Pain

  This study is testing if a new type of CT scan can help doctors better diagnose myocarditis and other causes of chest pain in patients who might not have heart disease.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06804278

• CD30-targeted bispecific-antibody‑armed autologous T-cell therapy for relapsed CD30-positive blood cancers

  This treatment will try using a patient's own T cells armed with a CD30/CD3 bispecific antibody to treat adults with relapsed or refractory CD30-positive blood cancers.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05544968

• LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma

  This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.

  Recruiting Phase 1 Leukos Biotech S.L. · Barcelona, Barcelona · NCT07914348

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma

  This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07779018

• Understanding heart artery disease using biomarkers and imaging in Oxford

  Researchers in Oxford are testing how biomarkers and advanced imaging can help explain why some heart artery plaques are unstable and how this affects heart damage after a heart attack.

  Recruiting University of Oxford · Oxford · NCT07772570

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.